Announcement on Holding Subsidiary Second Pharma Co., Ltd. Passing GMP Compliance Inspection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Holding Subsidiary Second Pharma Co., Ltd. Passing GMP Compliance Inspection
Filed with SSE ·
6ix hasn’t read this filing yet.
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on the Receipt of the Drug Supplement Approval Notice for Potassium Chloride Injection by Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
- Announcement on Obtaining Drug Registration Certificate for Some Products by Wholly-owned Subsidiary
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on Establishment of Double-Crane Industry Fund and Related Party Transactions
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Resignation of Senior Management Member
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Peritoneal Dialysis Solution (Lactic Acid) Series
- Announcement on Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Tirofiban Hydrochloride and Sodium Chloride Injection
- Announcement on Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. Obtaining the Drug Registration Certificate for Bosentan Dispersible Tablets
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical